Peter Wung

434 total citations
20 papers, 270 citations indexed

About

Peter Wung is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Peter Wung has authored 20 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 11 papers in Hematology and 10 papers in Immunology. Recurrent topics in Peter Wung's work include Spondyloarthritis Studies and Treatments (17 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Peter Wung is often cited by papers focused on Spondyloarthritis Studies and Treatments (17 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Peter Wung collaborates with scholars based in United States, Germany and Japan. Peter Wung's co-authors include Désirée van der Heijde, In‐Ho Song, Atul Deodhar, Aileen L. Pangan, Mitsumasa Kishimoto, Yuanyuan Duan, Joachim Sieper, Filip Van den Bosch, Walter P. Maksymowych and Tae‐Hwan Kim and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Arthritis Research & Therapy.

In The Last Decade

Peter Wung

18 papers receiving 266 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Wung United States 6 236 151 121 24 23 20 270
Andrea Everding United States 3 271 1.1× 177 1.2× 141 1.2× 32 1.3× 25 1.1× 5 318
Aimee Hanson Australia 7 152 0.6× 130 0.9× 67 0.6× 25 1.0× 12 0.5× 12 253
Pablo Coto Spain 10 194 0.8× 248 1.6× 89 0.7× 18 0.8× 21 0.9× 22 332
Lenore Noonan United States 4 206 0.9× 191 1.3× 112 0.9× 9 0.4× 27 1.2× 8 273
Graziella Carella Italy 8 72 0.3× 152 1.0× 52 0.4× 16 0.7× 27 1.2× 15 211
Rajan Bajracharya United Kingdom 7 230 1.0× 249 1.6× 115 1.0× 10 0.4× 6 0.3× 21 301
Jean-Pierre Cédoz France 7 124 0.5× 85 0.6× 39 0.3× 12 0.5× 12 0.5× 9 197
Roman Puliaev United States 11 122 0.5× 264 1.7× 56 0.5× 27 1.1× 9 0.4× 15 318
Anna Baratelle United States 5 301 1.3× 176 1.2× 163 1.3× 5 0.2× 20 0.9× 6 347
Ash Maroof United Kingdom 4 114 0.5× 228 1.5× 68 0.6× 21 0.9× 5 0.2× 5 270

Countries citing papers authored by Peter Wung

Since Specialization
Citations

This map shows the geographic impact of Peter Wung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Wung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Wung more than expected).

Fields of papers citing papers by Peter Wung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Wung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Wung. The network helps show where Peter Wung may publish in the future.

Co-authorship network of co-authors of Peter Wung

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Wung. A scholar is included among the top collaborators of Peter Wung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Wung. Peter Wung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bosch, Filip Van den, Atul Deodhar, Denis Poddubnyy, et al.. (2025). Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Research & Therapy. 27(1). 23–23.
2.
3.
4.
Bosch, Filip Van den, Atul Deodhar, Denis Poddubnyy, et al.. (2024). Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial. ACR Open Rheumatology. 6(8). 470–480. 3 indexed citations
5.
Blockmans, Daniël, Wolfgang Schmidt, Andrea Rubbert‐Roth, et al.. (2024). LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL. Annals of the Rheumatic Diseases. 83. 232–233. 9 indexed citations
6.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2023). POS1541 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY. Annals of the Rheumatic Diseases. 82. 1137–1138. 1 indexed citations
7.
Baraliakos, Xenofon, Désirée van der Heijde, Joachim Sieper, et al.. (2023). Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Research & Therapy. 25(1). 172–172. 12 indexed citations
8.
Poddubnyy, Denis, Dirk Elewaut, Victoria Navarro‐Compán, et al.. (2023). OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases. 82. 40–41. 2 indexed citations
9.
Bosch, Filip Van den, Atul Deodhar, Denis Poddubnyy, et al.. (2023). POS0250 PLACEBO-CONTROLLED EFFICACY AND SAFETY OF UPADACITINIB THROUGH ONE YEAR IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases. 82. 361–362. 2 indexed citations
10.
Mease, Philip J., Arathi R. Setty, Kim Papp, et al.. (2023). Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clinical and Experimental Rheumatology. 41(11). 2286–2297. 2 indexed citations
11.
Baraliakos, Xenofon, D. van der Heijde, Joachim Sieper, et al.. (2023). POS1122 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: ONE-YEAR RESULTS FROM A PHASE 3 STUDY. Annals of the Rheumatic Diseases. 82. 887–888. 1 indexed citations
12.
Kiltz, Uta, Mitsumasa Kishimoto, Jessica A. Walsh, et al.. (2023). Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatology and Therapy. 10(4). 887–899. 3 indexed citations
13.
Bosch, Filip Van den, Percival D. Sampaio‐Barros, Kristin M. D’Silva, et al.. (2023). POS1108 EFFICACY OF UPADACITINIB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN EARLY VERSUS ESTABLISHED DISEASE. 877–878. 1 indexed citations
14.
Heijde, Désirée van der, Xenofon Baraliakos, Joachim Sieper, et al.. (2022). Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases. 81(11). 1515–1523. 79 indexed citations
15.
Heijde, Désirée van der, Atul Deodhar, Walter P. Maksymowych, et al.. (2022). Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 8(2). e002280–e002280. 32 indexed citations
16.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2022). Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatology and Therapy. 10(1). 275–292. 28 indexed citations
17.
Deodhar, Atul, Filip Van den Bosch, Denis Poddubnyy, et al.. (2022). Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 400(10349). 369–379. 86 indexed citations
18.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2022). POS0081 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY. Annals of the Rheumatic Diseases. 81. 260–261. 1 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Everding Breakdown of academic impact, for papers by Aimee Hanson Breakdown of academic impact, for papers by Pablo Coto Breakdown of academic impact, for papers by Lenore Noonan Breakdown of academic impact, for papers by Graziella Carella Breakdown of academic impact, for papers by Rajan Bajracharya Breakdown of academic impact, for papers by Jean-Pierre Cédoz Breakdown of academic impact, for papers by Roman Puliaev Breakdown of academic impact, for papers by Anna Baratelle Breakdown of academic impact, for papers by Ash Maroof
Rankless by CCL
2026